Chitosan Drug Delivery Vehicle

About Karamedica

Karamedica is a private, pre-revenue biotech company developing a proprietary non-thermal plasma technology to decontaminate chitosan, a promising but sterilization-sensitive biopolymer derived from crustacean shells. This platform overcomes a major historical barrier, allowing chitosan to be used in implantable medical devices and targeted drug delivery systems. The company's initial pipeline focuses on an implantable hemostatic device for surgery and drug delivery vehicles for superficial bladder cancer and cerebral amyloid angiopathy (CAA), a condition linked to Alzheimer's disease.

About Karamedica

Karamedica is a private, pre-revenue biotech company developing a proprietary non-thermal plasma technology to decontaminate chitosan, a promising but sterilization-sensitive biopolymer derived from crustacean shells. This platform overcomes a major historical barrier, allowing chitosan to be used in implantable medical devices and targeted drug delivery systems. The company's initial pipeline focuses on an implantable hemostatic device for surgery and drug delivery vehicles for superficial bladder cancer and cerebral amyloid angiopathy (CAA), a condition linked to Alzheimer's disease.

Therapeutic Areas